Similarly, biomarker analysis of MONALEESA-3 demonstrated consistent benefit from ribociclib plus fulvestrant, irrespective of PIK3CA alteration status, as detected in baseline circulating tumor DNA (35). Here, PIK3CA is linked to neoplasm.